Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Challenges in tuberculosis drug research and development

Ann M Ginsberg¹, Melvin Spigelman

¹Global Alliance for TB Drug Development, New York, New York, USA. ann.ginsberg@tballiance.org

Nature Medicine

|March 8, 2007

Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.

Antimicrobial agents and chemotherapy·2024

Same author

Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.

The Lancet. Infectious diseases·2024

Same author

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.

The Lancet. Respiratory medicine·2023

Same author

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.

The New England journal of medicine·2022

Same author

Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.

The New England journal of medicine·2022

Same author

Reply to Kaye and Belley, "Third-Generation Cephalosporin-Resistant <i>Enterobacterales</i> Are Critical Priority Pathogens, Too!"

Antimicrobial agents and chemotherapy·2022